Krauss to Speak at ‘Mini Boot Camp’ on Working with Investors

Dr. Marlene Krauss, managing director of KBL Healthcare Ventures, Inc., an entity that funds innovative healthcare companies, will participate as a panelist in the upcoming Cornell Center for Technology Enterprise & Commercialization (CCTEC) “Mini Boot Camp” on February 27, 2013.

The event, to be held from 3 pm to 6:30 pm at the Weill Greenberg Center at Weill Cornell Medical College at 305 York Avenue in Manhattan, will feature a panel of experts providing advice for new business ventures.  Topics include funding and positioning early stage companies as well as the legal aspects of starting a company.

As managing director of KBL Healthcare Ventures, Dr. Krauss has founded and invested in numerous groundbreaking healthcare companies, including Summit Autonomous, Inc., which manufactures the Summit Technology excimer laser, the first laser to be approved by the FDA for refractive eye surgery; now known as LASIK.

Dr. Krauss received a B.A. from Cornell University, an M.B.A. from Harvard Graduate School of Business Administration and an M.D. from Harvard Medical School. She trained at the Harvard affiliated hospitals, the Beth Israel Hospital and the Deaconess Hospital, as well as Mt. Sinai Hospital in New York. She completed her training as a vitreoretinal surgeon at New York Hospital in 1985 and was a Clinical Instructor of Ophthalmology at New York Hospital and is a Board Certified Ophthalmologist.

Neuronetics Receives Phoenix Award

Neuronetics, Inc.’s NeuroStar TMS Therapy® System recently posted on its site, www.neuronetics.com, that it received the Phoenix 2012 Most Promising New Product Award at the 19th annual Phoenix Conference. Each year, Phoenix, the medical device and diagnostic conference for chief executive officers, presents awards to exceptional individuals and companies representing the medical device and diagnostic industry. Neuronetics is a privately-held medical device company committed to the development of innovative, non-invasive therapies to treat psychiatric conditions.

Depression affects about 20 million Americans annually, causing a range of physically and emotionally debilitating symptoms, including anxiousness, sadness, irritability, fatigue, changes in sleep patterns, loss of interest in previously enjoyable activities and digestive problems. It is estimated that about four million patients do not benefit from standard treatments for depression, even after repeated treatment attempts.

The NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy System is a non-invasive, non-drug therapeutic device that delivers magnetic resonance imaging (MRI)-strength, pulsed magnetic fields to stimulate nerve cells in the part of the brain thought to control mood. The NeuroStar TMS Therapy® System is the first and only TMS system cleared by the US FDA for major depressive disorder (MDD). It has been proven to be safe and effective for patients with MDD who have not benefitted from antidepressant medication. The goal of NeuroStar TMS Therapy is remission from depression without the side effects typical of antidepressant medications.